You Position: Home > Paper
Advances on chemoresistance mechanisms of non-small cell lung cancer
( views:246, downloads:4 )
- Author:
- No author available
- Journal Title:
- INTERNATIONAL JOURNAL OF RESPIRATION
- Issue:
- 16
- DOI:
- 10.3760/cma.j.issn.1673-436X.2007.16.014
- Key Word:
- 非小细胞肺癌;化疗;耐药性
Abstract： 非小细胞肺癌(NSCLC)是发病率和病死率都很高的恶性肿瘤,严重危害人类健康,目前临床对于该病仍以化疗为主.然而,肿瘤耐药性的产生严重影响了肿瘤细胞对化疗药物的敏感性,是导致化疗失败的最主要原因之一.肿瘤的耐药机制错综复杂,现有研究认为,化疗药物在肿瘤细胞内的有效药物浓度不足、肿瘤内活性蛋白通过干扰药物作用机制而降低药物活性、肿瘤细胞自身的DNA修复功能及细胞凋亡相关因子的异常等是引起耐药的几个主要原因.
- [1]Sikic BI,Dumontet C.Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.[J].1999,17(3).
- [2]Klinke F,Vogt U,Bielawski K,etc.p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.[J].2002,128(3).
- [3]Itoh T,Isobe H,Kinoshita I,etc.Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.[J].2003,94(4).
- [4]T, Hida,Y, Ariyoshi,M, Kuwabara,etc.Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity.[J].1993,23.
- [5]Corey DR,Huffman KE.Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line[J].2005,44(7).
- [6]Bergman AM,Vermorken JB,Peters GJ,etc.Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.[J].1999,80(7).
- [7]Suyama H,Igishi T,Sano H,etc.ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells.[J].2004,24(6).
- [8]Xin MG,Deng XM.Nicotine inactivation of the proapoptotic function of Bax through phosphorylation[J].2005,280(11).
- [9]Tonato M,Taron M,Stephens C,etc.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.[J].2003,22(23).
- [10]Gately DP,Howell SB.Cellular accumulation of the anticancer agent cisplatin: A review[J].1993.
- [11]Harrington D,Johnson DH,Belani CP,etc.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.[J].2002,346(2).
- [12]Klimstra DS,Catalano E,Green MR,etc.Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.[J].2002,20(5).
- [13]M, Volm,J, Mattern.Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.[J].1992,13.
- [14]Andries M, Bergman,Herbert M, Pinedo,Godefridus J, Peters.Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).[J].2002,5(1).